Patents by Inventor Lars Soegaard Nielsen
Lars Soegaard Nielsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180344846Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: ApplicationFiled: August 8, 2018Publication date: December 6, 2018Applicant: Symphogen A/SInventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
-
Patent number: 10058610Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: GrantFiled: November 14, 2016Date of Patent: August 28, 2018Assignee: Symphogen A/SInventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
-
Patent number: 9856691Abstract: A sliding window assembly (35) including a window frame and at least two glass panes (38, 39). At least one of the glass panes (38, 39) slides within the frame between an open position and a closed position, wherein one of the edges of each pane overlaps to form overlapping edges (42, 43). First and second rails (44, 45) are connected to the overlapping edges (42, 43) and cooperate to form a seal between them in the closed position. Each rail (44, 45) is formed from a metal component (46) and a plastic component (51) that are formed separate from each other and are assembled in nesting connection. The seal in the overlap between the overlapping edges (42, 43) in the closed position of the panes (38, 39) is formed between the plastic components (51) of the first and second rails (44, 45). The metal components (51) of the first and second rails (44, 45) are spaced from contact with each other and extend to overlie outwardly facing surfaces of the first and second panes (38, 39).Type: GrantFiled: December 21, 2015Date of Patent: January 2, 2018Assignee: JELD-WEN, Inc.Inventors: Lars Søgaard Nielsen, Richard James Mckenna
-
Publication number: 20170165365Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: ApplicationFiled: November 14, 2016Publication date: June 15, 2017Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
-
Patent number: 9527913Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: GrantFiled: May 2, 2013Date of Patent: December 27, 2016Assignee: SYMPHOGEN A/SInventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
-
Publication number: 20160186484Abstract: A sliding window assembly (35) including a window frame and at least two glass panes (38, 39). At least one of the glass panes (38, 39) slides within the frame between an open position and a closed position, wherein one of the edges of each pane overlaps to form overlapping edges (42, 43). First and second rails (44, 45) are connected to the overlapping edges (42, 43) and cooperate to form a seal between them in the closed position. Each rail (44, 45) is formed from a metal component (46) and a plastic component (51) that are formed separate from each other and are assembled in nesting connection. The seal in the overlap between the overlapping edges (42, 43) in the closed position of the panes (38, 39) is formed between the plastic components (51) of the first and second rails (44, 45). The metal components (51) of the first and second rails (44, 45) are spaced from contact with each other and extend to overlie outwardly facing surfaces of the first and second panes (38, 39).Type: ApplicationFiled: December 21, 2015Publication date: June 30, 2016Inventors: Lars Søgaard Nielsen, Richard James Mckenna
-
Publication number: 20150086478Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: ApplicationFiled: May 2, 2013Publication date: March 26, 2015Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
-
Patent number: 8202973Abstract: The present invention relates to a novel method for preparing vitamin K-dependent proteins. Furthermore the present invention relates to novel co-transfected eucaryotic host cells and recombinant vectors to be used in this improved method for preparing vitamin K-dependent proteins.Type: GrantFiled: October 2, 2001Date of Patent: June 19, 2012Assignee: Novo Nordisk Health Care AGInventors: Else Marie Nicolaisen, Lars Soegaard Nielsen
-
Publication number: 20110117605Abstract: The invention relates to methods for manufacturing drug products comprising at least two distinct members of a polyclonal protein, for example a polyclonal antibody, where each distinct member is expressed by a separate population of cells. The methods involve at least an initial step in which the cell populations expressing the distinct members of the polyclonal protein are cultured separately. The individual cell populations, or proteins expressed by the individual cell populations, are combined at a later point of the upstream or downstream processing to result in a single drug product comprising the distinct members of the polyclonal protein.Type: ApplicationFiled: April 23, 2009Publication date: May 19, 2011Applicant: Symphogen A/SInventors: Anne Bondgaard Tolstrup, Lars Soegaard Nielsen, Dietmar Weilguny, Christian Müller, Finn C. Wiberg, Jonas Heilskov Graversen
-
Patent number: 7910332Abstract: The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the collection, which encodes a distinct member of a polyclonal protein. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence is introduced into the cells by transfection with a collection of vectors. The present method is suitable for manufacturing recombinant polyclonal antibodies for therapeutic uses.Type: GrantFiled: May 23, 2008Date of Patent: March 22, 2011Assignee: Symphogen A/SInventors: Lars Soegaard Nielsen, Dietmar Weilguny, Anne Bondgaard Tolstrup, Finn C. Wiberg, Christian Muller
-
Publication number: 20100069262Abstract: The invention relates to a procedure for linking cognate pairs of VH and VL encoding sequences from a population of avian cells enriched in particular surface antigen markers. The linking procedure involves a multiplex molecular amplification procedure capable of linking nucleotide sequences of interest in connection with the amplification (multiplex PCR). The method is particularly advantageous for the generation of cognate pair libraries as well as combinatorial libraries of antibody variable region encoding sequences from chickens or other birds. The invention also provides methods for generation of chimeric human/avian antibodies and expression libraries generated by such methods.Type: ApplicationFiled: August 28, 2009Publication date: March 18, 2010Applicant: Symphogen A/SInventors: Lars Soegaard Nielsen, Charles Pyke, Anne Marie V. Jensen, Klaus Koefoed, Allan Jensen, Mette Thorn
-
Publication number: 20090111142Abstract: The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the collection, which encodes a distinct member of a polyclonal protein. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence is introduced into the cells by transfection with a collection of vectors. The present method is suitable for manufacturing recombinant polyclonal antibodies for therapeutic uses.Type: ApplicationFiled: May 23, 2008Publication date: April 30, 2009Inventors: Lars Soegaard Nielsen, Dietmar Weilguny, Anne Bondgaard Tolstrup, Finn C. Wiberg, Christian Muller
-
Publication number: 20080299581Abstract: The present invention relates to the field of molecular cloning and to the field of expression cloning in higher, eukaryotic cells. In particular, the present invention relates to a method for fast and reliable identification of vectors and vector DNA which will be capable of providing a desired expression product if a eukaryotic host cell is transfected with the vector DNA.Type: ApplicationFiled: May 23, 2008Publication date: December 4, 2008Inventors: Lars Soegaard Nielsen, Per-Johan Meijer
-
Publication number: 20040058413Abstract: The present invention relates to a novel method for preparing vitamin K-dependent proteins. Furthermore the present invention relates to novel co-transfected eucaryotic host cells and recombinant vectors to be used in this improved method for preparing vitamin K-dependent proteins.Type: ApplicationFiled: September 2, 2003Publication date: March 25, 2004Inventors: Else Marie Nicolaisen, Lars Soegaard Nielsen
-
Publication number: 20020160458Abstract: Disclosed is a method for high efficiency release of recombinant proteins in eukaryotic cells and more specifically, for enhancing the secretion of Factor VII by co-expression of kex2 endoprotease with FVII in cells of mammalian origin.Type: ApplicationFiled: November 13, 2001Publication date: October 31, 2002Inventors: Helle Woldike, Finn Wiberg, Lars Soegaard Nielsen
-
Patent number: 6329176Abstract: Disclosed is a method for high efficiency release of recombinant proteins in eukaryotic cells and more specifically, for enhancing the secretion of Factor VII by co-expression of kex2 endoprotease with FVII in cells of mammalian origin.Type: GrantFiled: April 25, 2000Date of Patent: December 11, 2001Assignee: Novo Nordisk A/SInventors: Helle Wöldike, Finn Wiberg, Lars Søegaard Nielsen